Format

Send to

Choose Destination
Neuromodulation. 2005 Jul;8(3):176-81. doi: 10.1111/j.1525-1403.2005.05236.x.

Lower urinary tract and bowel disorders and multiple sclerosis: role of sacral neuromodulation: a preliminary report.

Author information

1
Institute of Urology, Università Politecnica delle Marche Medical School, Azienda Ospedaliera Ospedali, Riuniti, Ancona, Italy.

Abstract

OBJECTIVE:

  In the present study we wanted to determine whether sacral neuromodulation benefits patients with bladder and bowel symptoms caused by multiple sclerosis (MS).

METHODS:

  At our Institute, five patients with MS underwent unilateral implantation of a sacral neuromodulation system, InterStim (Medtronic Inc., Minneapolis, Minnesota, USA), between April 2001 and June 2002; the mean follow-up was 30.4 months (range 24-38). The following parameters were evaluated before and after implant of the neurostimulator device: number of daily voidings, number of incontinent episodes, residual urine, Wexner score, quality of life (QoL), and psychological impact.

RESULTS:

  There was an overall 81.4% decrease of urgency and frequency with a significant decrease in the number of upper urinary tract infections and fever; there was a slight improvement in bowel function; there was an overall 51.8% improvement in the QoL and a discernible improvement emotional well-being.

CONCLUSIONS:

  Unilateral chronic sacral neuromodulation can be a valuable treatment for neurogenic bladder and bowel disorders associated with MS.

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center